甘精胰岛素合用格列美脲与门冬胰岛素30治疗2型糖尿病的对比观察

Comparison of insulin glargine combined with glimepiride and BIAsp 30 in treatment of type 2 diabetes

目的比较甘精胰岛素合用格列美脲与诺和锐30治疗口服降糖药未达标的2型糖尿病患者的疗效与低血糖发生的风险。方法 62例血糖控制未达标的2型糖尿病患者,随机分为甘精胰岛素合用格列美脲组31例(A组)与诺和锐30治疗组31例(B组),治疗12周。结果两组治疗后FPG、2 hPG、HbA1c均较治疗前明显下降(P<0.01),治疗后两组间比较差异无统计学意义(P>0.05),低血糖发生率A组低于B组(P<0.05)。两组均无严重不良事件发生。结论甘精胰岛素联合格列美脲与门冬胰岛素30两种方案都能使血糖有效达标,甘精胰岛素组低血糖发生率低、对患者体重影响小、使用方便、患者依从性好。

Objective To compare insulin glargine combined with the risk of Glimepiride and aspart 30 treatment of oral hypoglycemic agents in patients with type 2 diabetes did not meet the efficacy and low blood sugar. Methods All of 62 pa- tients glycemie control did not meet the Type 2 diabetic patients were randomly divided into the reorganization of the corn bination of insulin glargine to glimepiride group of 31 cases （group A） and aspart 30 treatment group, 31 cases （B group）, 12 weeks of treatment. Results After treatment, FPG, 2 hPG, HbAlc compared with treatment decreased significantly （P 〈 0.01） after treatment, no significant difference between the two groups （P 〉 0.05）, the incidence of hypoglycemia was lower than group B （P 〈 0.05）. There were no serious adverse events. Conclusion The insulin glargine with glimepiride tablets and aspartate insulin 30 two kinds of programs can make blood glucose effective compliance, insulin glargine group of low blood sugar low incidence, little impact on patient weight, easy to use, good patient compliance.